Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Asian Market Preview: Nikkei Futures +0.65%, Hang Seng Futures +0.70%, ASX SPI 200 +0.20%, S&P Futures +0.09%

Oct 23 ,2025

  • Synopsis:

    • Asian markets set for positive start to Friday trade. Futures signaling opening gains in Japan and Hong Kong. ASX also off to positive start. S&P 500 futures steady afterhours following another tech-led advance on Thursday. Australian yield curve steepening after Treasuries weakened. FX markets steady with dollar nearing two-week high against yen. Crude off overnight highs following Thursday's geopolitical-driven rally. Gold stabilizing following big Tuesday selloff. Bitcoin continues to fluctuate.

    • White House confirmed President Trump to meet China's Xi at APEC summit on 30-Oct following days of speculation whether meeting will go ahead. While Trump has voiced optimism of a deal with Xi, meeting occurs against backdrop of elevated tensions amid reports US readying curbs on exports of critical software and a probe into China's noncompliance with 2020 trade deal. Fentanyl, rare earths and soybeans expected to feature in talks though meeting not expected to produce anything substantive beyond another truce and directives to continue negotiations.

    • Lot of press discussion about expected near-term impact on crude flows to China and India from US sanctions on Russian oil majors. Sources said state importers in both countries expected to halt purchases of seaborne Russian crude, at least in short-term. However, questions over sanctions compliance and effectiveness remain. Separately, EU announced ban on Russian LNG imports and imposed sanctions on firms including China refiners, prompting rebuke by Commerce Ministry spokesman.

    • Elsewhere, few surprises out of China's fourth plenum, which concluded Thursday with five-year plan focused on areas such as technological self-reliance and advanced manufacturing. Emphasized determination to meet 2025 growth target, repeating macro policies will be strengthened at appropriate time. Meanwhile, Reuters sources said Nexperia's China unit has resumed shipments of semiconductors to local distributors but with caveat that payments settled in yuan while Nexperia seeking alternative packaging partners outside China.

  • Pre-open Company News:

    • THD.VN -- Thaiholdings reports Q3 NPAT VND23.69B, (8%) vs year-ago VND25.67B

    • 507880.IN -- INR388/share open offer for 26.03% stake in VIP Industries to run from 3-Nov through 17-Nov

    • 1138.HK -- COSCO SHIPPING Energy Transportation completes 694.4M A-shares placement at CNY11.52/share

    • 002683.CH -- Guangdong Hongda Holdings Group reports Q3 net income attributable CNY149.5M, (37%) vs year-ago CNY237.0M

    • 1052.HK -- Yuexiu Transport Infrastructure reports August toll revenues

    • 600160.CH -- Zhejiang Juhua provides 9M operational data

    • 603529.CH -- AIMA Technology Group reports Q3 net income attributable CNY694.8M, +15.3% y/y

    • 917.HK -- Qunabox Group receives management voluntary lock-up notice for a period of 12 months starting today

    • S63.SP -- Singapore Technologies Engineering reports Q3 contracts secured worth SG$4.9B

    • 300014.CH -- EVE Energy reports Q3 net income attributable CNY1.21B vs FactSet CNY1.41B [2 est, CNY1.24-1.58B]

    • 300124.CH -- Shenzhen Inovance Technology reports Q3 net income attributable CNY1.29B vs FactSet CNY1.41B [2 est, CNY1.41-1.41B]

    • 600989.CH -- Ningxia Baofeng Energy Group reports Q3 net income attributable CNY3.23B vs FactSet CNY3.59B [2 est, CNY3.55-3.62B

    • MRK -- FDA grants Priority Review for Merck's KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph), each in combination with Padcev (enfortumab vedotin-ejfv), for certain patients with muscle-invasive bladder cancer

    • 000877.CH -- Tianshan Material Co. reports Q3 net income attributable (CNY258.8M) vs year-ago (CNY334.2M)

  • On Deck:

    • China:

      • Economic:

        • 08:00 CST: Foreign Direct Investment Y/Y; consensus

      • Earnings:

        • Shanjin International Gold (000975.CH), Zhejiang Supor (002032.CH), Hua Xia Bank (600015.CH), WuXi AppTec (603259.CH)

    • Hong Kong:

      • Earnings:

        • China Overseas Land & Investment (688.HK), Sinopharm Group (1099.HK), China Resources Building Materials Technology Holdings (1313.HK), China National Building Material (3323.HK)

    • Japan:

      • Economic:

        • 08:30 JST: CPI National Y/Y; consensus

        • 08:30 JST: CPI Core National Y/Y; consensus

        • 08:30 JST: CPI ex-Fresh Food and Energy; consensus +3%

        • 14:00 JST: Leading Index (Final); consensus

      • Earnings:

        • Shin-Etsu Chemical (4063.JP), Chugai Pharmaceutical (4519.JP), Canon Marketing Japan (8060.JP), JAFCO Group (8595.JP)

    • India:

      • Earnings:

        • Coforge (532541.IN), eClerx Services (532927.IN)

    • Thailand:

      • Earnings:

        • Delta Electronics (Thailand) Public (DELTA.TB)

  • Market Data:

    • Gold (Dec 25): ($17.60) or (0.42%) to $4128.00

    • WTI Crude (Dec 25): ($0.20) or (0.32%) to $61.59

    • $-¥: +0.66 or +0.43% to 152.6250

    • $-KRW: +3.74 or +0.26% to 1435.8400

    • A$-$: +0.00 or +0.37% to 0.6512

    • $-INR: +0.04 or +0.04% to 87.7791

    • $-CNY: (0.00) or (0.07%) to 7.1217

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE